1. Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III). Issue 2 (14th September 2017) Authors: Shafran, S. D.; Shaw, D.; Charafeddine, M.; Agarwal, K.; Foster, G. R.; Abunimeh, M.; Pilot‐Matias, T.; Pothacamury, R. K.; Fu, B.; Cohen, E.; Cohen, D. E.; Gane, E. Journal: Journal of viral hepatitis Issue: Volume 25:Issue 2(2018) Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗